Literature DB >> 9056003

Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.

G P Moran1, D J Sullivan, M C Henman, C E McCreary, B J Harrington, D B Shanley, D C Coleman.   

Abstract

Candida dubliniensis is a recently described species of Candida associated with oral candidiasis in human immunodeficiency virus (HIV)-infected individuals. Nineteen oral isolates of C. dubliniensis recovered from 10 HIV-positive and 4 HIV-negative individuals and one vaginal isolate from an additional HIV-negative subject were assessed for fluconazole susceptibility by broth microdilution (BMD), hyphal elongation assessment, and Etest. The susceptibilities of these 20 isolates to itraconazole and amphotericin B and of 10 isolates to ketoconazole were also determined by BMD only. Sixteen of the C. dubliniensis isolates were susceptible to fluconazole (MIC range, 0.125 to 1.0 microgram ml-1), and four (recovered from two AIDS patients) were fluconazole resistant (MIC range, 8 to 32 micrograms ml-1). Fluconazole susceptibility data obtained by hyphal elongation assessment correlated well with results obtained by BMD, but the corresponding Etest MIC results were one to four times higher. All of the isolates tested were found to be sensitive to itraconazole, ketoconazole, and amphotericin B. Sequential exposure of two fluconazole-sensitive (MIC, 0.5 microgram ml-1) C. dubliniensis isolates to increasing concentrations of fluconazole in agar medium resulted in the recovery of derivatives which expressed a stable fluconazole-resistant phenotype (BMD-determined MIC range, 16 to 64 micrograms ml-1), even after a minimum of 10 consecutive subcultures on drug-free medium and following prolonged storage at -70 degrees C. The clonal relationship between the parental isolates and their respective fluconazole-resistant derivatives was confirmed by genomic DNA fingerprinting and karyotype analysis. The results of this study demonstrate that C. dubliniensis is inherently susceptible to commonly used antifungal drugs, that fluconazole resistance does occur in clinical isolates, and that stable fluconazole resistance can be readily induced in vitro following exposure to the drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056003      PMCID: PMC163761     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Azole drug resistance in Candida species.

Authors:  D W Warnock
Journal:  J Med Microbiol       Date:  1992-10       Impact factor: 2.472

Review 2.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

3.  Strain variation among and antifungal susceptibilities of isolates of Candida krusei.

Authors:  Y F Berrouane; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients.

Authors:  D Sullivan; D Bennett; M Henman; P Harwood; S Flint; F Mulcahy; D Shanley; D Coleman
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

Review 5.  Oral Candida in HIV infection and AIDS: new perspectives/new approaches.

Authors:  D C Coleman; D E Bennett; D J Sullivan; P J Gallagher; M C Henman; D B Shanley; R J Russell
Journal:  Crit Rev Microbiol       Date:  1993       Impact factor: 7.624

6.  Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation.

Authors:  P J Gallagher; D E Bennett; M C Henman; R J Russell; S R Flint; D B Shanley; D C Coleman
Journal:  J Gen Microbiol       Date:  1992-09

7.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

8.  A Candida albicans dispersed, repeated gene family and its epidemiologic applications.

Authors:  S Scherer; D A Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Genotype and phenotype of oral Candida albicans from patients infected with the human immunodeficiency virus.

Authors:  M J McCullough; B C Ross; B D Dwyer; P C Reade
Journal:  Microbiology       Date:  1994-05       Impact factor: 2.777

Review 10.  Impact of the changing epidemiology of fungal infections in the 1990s.

Authors:  M Pfaller; R Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

View more
  90 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  One-year prevalence of Candida dublinienis in a Dutch university hospital.

Authors:  J F Meis; F M Lunel; P E Verweij; A Voss
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions.

Authors:  W R Kirkpatrick; J L Lopez-Ribot; R K McAtee; T F Patterson
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 5.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

6.  Do hospital microbiology laboratories still need to distinguish Candida albicans from Candida dubliniensis?

Authors:  Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

7.  Development and evaluation of a rapid latex agglutination test using a monoclonal antibody to identify Candida dubliniensis colonies.

Authors:  Agnes Marot-Leblond; Bertrand Beucher; Sandrine David; Sandrine Nail-Billaud; Raymond Robert
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

8.  The usefulness of DNA sequencing after extraction by Whatman FTA filter matrix technology and phenotypic tests for differentiation of Candida albicans and Candida dubliniensis.

Authors:  Nuri Kiraz; Yasemin Oz; Huseyin Aslan; Hamza Muslumanoglu
Journal:  Mycopathologia       Date:  2014-01-17       Impact factor: 2.574

9.  In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.

Authors:  M A Pfaller; S A Messer; S Gee; S Joly; C Pujol; D J Sullivan; D C Coleman; D R Soll
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Candida dubliniensis at a university hospital in Saudi Arabia.

Authors:  R Fotedar; S S A Al-Hedaithy
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.